Ryan Michael Antar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Michael Antar has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Whalen
Department of Urology, School of Medicine, George Washington University, Washington, DC
9 shared publications - Vincent Eric Xu
Department of Urology, School of Medicine, George Washington University, Washington, DC
8 shared publications - Arthur Drouaud
George Washington University School of Medicine, Washington, DC, USA
6 shared publications Michael J. Whalen
4 shared publicationsArthur Drouaud
George Washington Univ, Dept Urol, Sch Med, 2300 1St, Washington, DC 20037 USA
3 shared publicationsChristian Farag
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by AME Publishing Company in AME Medical Journal
- Vol. 11, 26
Radical prostatectomy confers superior survival compared to radiotherapy with androgen deprivation in high-risk prostate cancer: a propensity score-matched analysis
Background: Radical prostatectomy (RP) and radiotherapy combined with androgen deprivation therapy (XRT + ADT) represent the standard definitive treatment strategies for high-risk prostatic adenocarcinoma. Using the National Cancer Database (NCDB), we compared the overall survival (OS) outcomes of RP, XRT + ADT, and secondary therapy (ST) to better understand the current landscape of treatment patterns and patient-specific prognosticators. Methods: Men with high-risk prostate cancer (PCa) were identified for this retrospective cohort study and had received either RP or XRT + ADT as their initial treatment course. XRT + ADT was defined as external beam radiation therapy (EBRT) to the prostate/pelvis, with ADT initiated within 90 days and having not first received RP. Clinical, demographic, and pathologic characteristics were obtained, and nearest neighbor propensity score matching without replacement using a 1:1 ratio was performed on significantly different clinicopathologic variables. Multiple logistic regression models were used to predict (I) the receipt of XRT + ADT as primary treatment and (II) the receipt of any ST. ST was defined as XRT ± ADT to the prostate/pelvis following initial RP. Survival analysis was performed using the Cox proportional hazards model and the Kaplan-Meier method. Results: A total of 86,282 men who underwent treatment between 2004 and 2019 met the inclusion and exclusion criteria; 64% underwent RP first, and 36% underwent XRT + ADT first. Following propensity score matching, a total of 61,468 patients were analyzed. After propensity matching, XRT + ADT patients were still more likely to be older and have Medicare insurance (all PConclusions: Our study suggests that while each modality has its risks and benefits, RP with or without the addition of ST may still provide better survival outcomes over XRT + ADT alone when utilized as the primary definitive treatment in appropriately selected high-risk patients.
- 1 September 2026
- Published by AME Publishing Company in AME Medical Journal
- Vol. 11, 26
Open AccessRadical prostatectomy confers superior survival compared to radiotherapy with androgen deprivation in high-risk prostate cancer: a propensity score-matched analysis
Background: Radical prostatectomy (RP) and radiotherapy combined with androgen deprivation therapy (XRT + ADT) represent the standard definitive treatment strategies for high-risk prostatic adenocarcinoma. Using the National Cancer Database (NCDB), we compared the overall survival (OS) outcomes of RP, XRT + ADT, and secondary therapy (ST) to better understand the current landscape of treatment patterns and patient-specific prognosticators. Methods: Men with high-risk prostate cancer (PCa) were identified for this retrospective cohort study and had received either RP or XRT + ADT as their initial treatment course. XRT + ADT was defined as external beam radiation therapy (EBRT) to the prostate/pelvis, with ADT initiated within 90 days and having not first received RP. Clinical, demographic, and pathologic characteristics were obtained, and nearest neighbor propensity score matching without replacement using a 1:1 ratio was performed on significantly different clinicopathologic variables. Multiple logistic regression models were used to predict (I) the receipt of XRT + ADT as primary treatment and (II) the receipt of any ST. ST was defined as XRT ± ADT to the prostate/pelvis following initial RP. Survival analysis was performed using the Cox proportional hazards model and the Kaplan-Meier method. Results: A total of 86,282 men who underwent treatment between 2004 and 2019 met the inclusion and exclusion criteria; 64% underwent RP first, and 36% underwent XRT + ADT first. Following propensity score matching, a total of 61,468 patients were analyzed. After propensity matching, XRT + ADT patients were still more likely to be older and have Medicare insurance (all PConclusions: Our study suggests that while each modality has its risks and benefits, RP with or without the addition of ST may still provide better survival outcomes over XRT + ADT alone when utilized as the primary definitive treatment in appropriately selected high-risk patients.
- Open Access
- 28 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70548
Bladder Cancer Incidence Trends in the United States From 2000 to 2020
Background: Bladder cancer is one of the most common urogenital cancers globally. Here, we aimed to report the incidence trend of bladder cancer in the United States (US) over 2000–2020, by age, sex, race/ethnicity, and types using Surveillance, Epidemiology, and End Results (SEER). Methods: We used SEER 22 data to calculate the age‐standardized and delay‐adjustment incidence rate of bladder cancer. Only individuals diagnosed with cancer and whose age at diagnosis was known were included in the study. A delay model was applied, adjusting for variables such as cancer site, registry, age group, race/ethnicity, and year of diagnosis. Using the Tiwari technique, the same database was also used to determine the age‐standardized incidence rate (ASIR) of subtypes. The incidence data for 2020 were excluded from Joinpoint trends while displayed separately in illustrations. Results: Over 2000–2019, most bladder cancer cases were urothelial carcinoma (92.99%), among non‐Hispanic Whites (84.48%) and those aged 70 to 84 years (45.72%). There was a significant decrease in the ASIR of bladder cancer across all races/ethnicities in both sexes within all age groups (Average annual percent change (AAPC): −0.95%; [−1.06, −0.83] for men and −1.02% [−1.21, −0.84] for women) over 2000–2019. The incidence rates decreased by 6.23% during the COVID‐19 pandemic. Also, the delay‐adjusted incidence rate of bladder cancer increased with advancing age. Conclusions: Despite a decrease in ASIR of bladder cancer over 2000–2019, there are still a high number of incident cases, particularly among NHWs and the elderly. Future studies should investigate the underlying causes of bladder cancer incidence trends among demographic groups.
- 28 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70548
Open AccessBladder Cancer Incidence Trends in the United States From 2000 to 2020
Background: Bladder cancer is one of the most common urogenital cancers globally. Here, we aimed to report the incidence trend of bladder cancer in the United States (US) over 2000–2020, by age, sex, race/ethnicity, and types using Surveillance, Epidemiology, and End Results (SEER). Methods: We used SEER 22 data to calculate the age‐standardized and delay‐adjustment incidence rate of bladder cancer. Only individuals diagnosed with cancer and whose age at diagnosis was known were included in the study. A delay model was applied, adjusting for variables such as cancer site, registry, age group, race/ethnicity, and year of diagnosis. Using the Tiwari technique, the same database was also used to determine the age‐standardized incidence rate (ASIR) of subtypes. The incidence data for 2020 were excluded from Joinpoint trends while displayed separately in illustrations. Results: Over 2000–2019, most bladder cancer cases were urothelial carcinoma (92.99%), among non‐Hispanic Whites (84.48%) and those aged 70 to 84 years (45.72%). There was a significant decrease in the ASIR of bladder cancer across all races/ethnicities in both sexes within all age groups (Average annual percent change (AAPC): −0.95%; [−1.06, −0.83] for men and −1.02% [−1.21, −0.84] for women) over 2000–2019. The incidence rates decreased by 6.23% during the COVID‐19 pandemic. Also, the delay‐adjusted incidence rate of bladder cancer increased with advancing age. Conclusions: Despite a decrease in ASIR of bladder cancer over 2000–2019, there are still a high number of incident cases, particularly among NHWs and the elderly. Future studies should investigate the underlying causes of bladder cancer incidence trends among demographic groups.
- Open Access
- 1 September 2025
- Published by Elsevier in Urology Case Reports
- Vol. 63, 103183
Metachronous nodal metastases from HPV-associated penile carcinoma in situ
- 1 September 2025
- Published by Elsevier in Urology Case Reports
- Vol. 63, 103183
Open AccessMetachronous nodal metastases from HPV-associated penile carcinoma in situ
- 10 February 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (3) , 102316
Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry
- 10 February 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (3) , 102316
Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry
- Open Access
- 6 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6909-6937
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.
- 6 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6909-6937
Open AccessThe Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.
- 28 September 2024
- Published by Elsevier in Clinical Radiology
- Vol. 81, 106709
Dual-energy subtraction radiography (DESR): a systematic review and meta-analysis of pulmonary nodule detection
- 28 September 2024
- Published by Elsevier in Clinical Radiology
- Vol. 81, 106709
Dual-energy subtraction radiography (DESR): a systematic review and meta-analysis of pulmonary nodule detection
- 17 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102224
Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma
- 17 September 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (6) , 102224
Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma
- Open Access
- 1 August 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (8) , 1349-1363
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer
Background: Partial cystectomy (PC) offers potential benefits for select patients with muscle-invasive bladder cancer (MIBC). However, the oncologic efficacy of PC may be compromised due to the underutilization of standard-of-care modalities, such as neoadjuvant chemotherapy (NAC) and pelvic lymph node dissection (PLND). We aimed to assess factors influencing the incorporation of NAC and PLND with PC and evaluate their impact on overall survival (OS). Methods: We identified 2,832 patients with cT2-4N0M0 bladder cancer (BCa) who underwent PC between 2004 and 2019 using the National Cancer Database (NCDB). The primary endpoint was OS. Kaplan-Meier analysis compared OS in treatment modalities in PC patients. Multivariate Cox Proportional Hazards (CPH) model assessed the impact of age, sex, race, insurance, income, Charlson-Deyo Index (CDI), clinical T-stage, facility type, histology, surgical margins, NAC, PLND adequacy [≥10 lymph node (LN) yield], and adjuvant radiation treatment on OS. Multivariate logistic regressions were performed to examine predictors of NAC and PLND receipt in PC patients. Results: Two hundred and thirty-one patients received multi-agent NAC with PC. NAC treatment with PLND was associated with significantly improved OS (P80 years old, CDI >2, cT3-4, positive margins, and adjuvant radiation all increased adjusted mortality risk. After controlling for clinicopathologic variables, females were less likely to receive PLND [odds ratio (OR) 0.719, P=0.005], while NAC was more likely administered to PC patients diagnosed from 2016–2019 (OR 5.295, PConclusions: Despite guideline recommendations, the utilization of NAC and PLND with PC remains insufficient. Our analysis underscores the significant OS benefit of these recommended treatments as part of MIBC care. Importantly, we highlight a gradual increase in NAC and PLND receipt in recent years, centered largely at academic facilities. Notably, gender disparities exist in PLND receipt, emphasizing the need for further investigation.
- 1 August 2024
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 13 (8) , 1349-1363
Open AccessOncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer
Background: Partial cystectomy (PC) offers potential benefits for select patients with muscle-invasive bladder cancer (MIBC). However, the oncologic efficacy of PC may be compromised due to the underutilization of standard-of-care modalities, such as neoadjuvant chemotherapy (NAC) and pelvic lymph node dissection (PLND). We aimed to assess factors influencing the incorporation of NAC and PLND with PC and evaluate their impact on overall survival (OS). Methods: We identified 2,832 patients with cT2-4N0M0 bladder cancer (BCa) who underwent PC between 2004 and 2019 using the National Cancer Database (NCDB). The primary endpoint was OS. Kaplan-Meier analysis compared OS in treatment modalities in PC patients. Multivariate Cox Proportional Hazards (CPH) model assessed the impact of age, sex, race, insurance, income, Charlson-Deyo Index (CDI), clinical T-stage, facility type, histology, surgical margins, NAC, PLND adequacy [≥10 lymph node (LN) yield], and adjuvant radiation treatment on OS. Multivariate logistic regressions were performed to examine predictors of NAC and PLND receipt in PC patients. Results: Two hundred and thirty-one patients received multi-agent NAC with PC. NAC treatment with PLND was associated with significantly improved OS (P80 years old, CDI >2, cT3-4, positive margins, and adjuvant radiation all increased adjusted mortality risk. After controlling for clinicopathologic variables, females were less likely to receive PLND [odds ratio (OR) 0.719, P=0.005], while NAC was more likely administered to PC patients diagnosed from 2016–2019 (OR 5.295, PConclusions: Despite guideline recommendations, the utilization of NAC and PLND with PC remains insufficient. Our analysis underscores the significant OS benefit of these recommended treatments as part of MIBC care. Importantly, we highlight a gradual increase in NAC and PLND receipt in recent years, centered largely at academic facilities. Notably, gender disparities exist in PLND receipt, emphasizing the need for further investigation.
- 27 July 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (5) , 102179
Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis
- 27 July 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (5) , 102179
Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis